Chest Pain is Associated With Decreased Irisin Serum Levels in Type 2 Diabetic Patients With Coronary Artery Disease

Document Type : Original Article

Authors

1 Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IR Iran.

2 Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences and Department of Biochemistry, Afzalipur Faculty of Medicine, Kerman University of Medical Sciences, Kerman, IR Iran.

3 Cardiovascular Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran.

Abstract

Background: This study aimed to determine irisin serum levels in type 2 diabetic patients with and without coronary artery disease (CAD).
Methods: This study was performed on 56 type 2 diabetic patients with and without CAD and 28 normal controls. The serum levels of irisin, HbA1c, and fasting blood sugar of all the participants and the severity of CAD in the diabetic patients were determined.
Results: The irisin serum level was significantly decreased in the CAD diabetic patients who were symptomatic. HbA1c had a moderate positive correlation with the SYNTAX score in the diabetic patients with CAD. The serum level of irisin was not significantly different between the evaluated groups.
Conclusions: Based on the results, decreased irisin may be considered a risk factor for type 2 diabetic patients with CAD. Accordingly, the evaluation of patients with decreased irisin serum levels regarding the prediction of heart infarcts may be valuable.

Keywords

References

1. Arababadi, M.K., et al., Nephropathic
complication of type-2 diabetes is following
pattern of autoimmune diseases? Diabetes
research and clinical practice, 2010. 87(1):
p. 33-37.
2. Olafsdottir, E., et al., The prevalence of
retinopathy in subjects with and without type
2 diabetes mellitus. Acta Ophthalmol, 2014.
92(2): p. 133-7.
3. Khan, A.R., et al., Knowledge, attitude and
practice of ministry of health primary health
care physicians in the management of type 2
diabetes mellitus: a cross-sectional study in
the Al Hasa District of Saudi Arabia, 2010.
Niger J Clin Pract, 2011. 14(1): p. 52-9.
4. Masoomi, M., S. Samadi, and M.
Sheikhvatan, Thrombolytic effect of
streptokinase infusion assessed by STsegment resolution between diabetic and
non-diabetic myocardial infarction patients.
Cardiol J, 2012. 19(2): p. 168-73.
5. Arababadi, M.K., et al., Nephropathic
complication of type-2 diabetes is following
pattern of autoimmune diseases? Diabetes
Res Clin Pract, 2010. 87(1): p. 33-7.
6. Franks, P.W. and J. Merino, Gene-lifestyle
interplay in type 2 diabetes. Curr Opin Genet
Dev, 2018. 50: p. 35-40.
7. Kuloglu, T., et al., Irisin: a potentially
candidate marker for myocardial infarction.
Peptides, 2014. 55: p. 85-91.
8. Roca-Rivada, A., et al., FNDC5/irisin is not
only a myokine but also an adipokine. PLoS
One, 2013. 8(4): p. e60563.
9. Moreno-Navarrete, J.M., et al., Irisin is
expressed and produced by human muscle
and adipose tissue in association with
obesity and insulin resistance. J Clin
Endocrinol Metab, 2013. 98(4): p. E769-78.
10. Fatahian, A., H. Nayeri, and M. Sadeghi,
Irisin, a new biomarker in diagnosis of
atherosclerosis and myocardial infarction. J
Isfahan Med Sch, 2015. 33(350): p. 1-11.
11. Choi, Y.K., et al., Serum irisin levels in
new-onset type 2 diabetes. Diabetes Res
Clin Pract, 2013. 100(1): p. 96-101.
12. Liu, J.J., et al., Lower circulating irisin is
associated with type 2 diabetes mellitus. J
Diabetes Complications, 2013. 27(4): p.
365-9.
13. Farooq, V., et al., Combined anatomical and
clinical factors for the long-term risk
stratification of patients undergoing
percutaneous coronary intervention: the
Logistic Clinical SYNTAX score. Eur Heart
J, 2012. 33(24): p. 3098-104.
14. Wang, H., et al., Irisin plays a pivotal role to
protect the heart against ischemia and
reperfusion injury. J Cell Physiol, 2017.
232(12): p. 3775-3785.
15. Chen, K., et al., Irisin protects mitochondria
function during pulmonary
ischemia/reperfusion injury. Sci Transl Med,
2017. 9(418).
16. Aydin, S., et al., The effect of iloprost and
sildenafil, alone and in combination, on
myocardial ischaemia and nitric oxide and
irisin levels. Cardiovasc J Afr, 2017. 28(6):
p. 389-396.
17. Peng, J., et al., Irisin protects against
neuronal injury induced by oxygen-glucose
deprivation in part depends on the inhibition
of ROS-NLRP3 inflammatory signaling
pathway. Mol Immunol, 2017. 91: p. 185-
194.
18. Bonfante, I.L.P., et al., Obese with higher
FNDC5/Irisin levels have a better metabolic
profile, lower lipopolysaccharide levels and
type 2 diabetes risk. Arch Endocrinol Metab,
2017. 61(6): p. 524-533.
19. Rana, K.S., et al., Plasma irisin is elevated in
type 2 diabetes and is associated with
increased E-selectin levels. Cardiovasc
Diabetol, 2017. 16(1): p. 147.
20. Pang, Y., et al., beta-arrestin-2 is involved in
irisin induced glucose metabolism in type 2
diabetes via p38 MAPK signaling. Exp Cell
Res, 2017. 360(2): p. 199-204.
21. Shelbaya, S., et al., Study of Irisin Hormone
Level in Type 2 Diabetic Patients and
Patients with Diabetic Nephropathy. Curr
Diabetes Rev, 2017. 29(85535): p.
1573399813666170829163442.
Iranian Heart Journal
Volume 21, Issue 1
January 2020
Pages 55-66

Files

Share

How to cite

Statistics